Pain treatment in renal colics; the role of Instanyl ® in prevention of hospitalization. A Clinical outcomes study.

Phase 4

• Conditions: colic pain; renal colic; 10046708

• Registration Number: NL-OMON37827
• Lead Sponsor: Isala Klinieken

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 30

Inclusion Criteria

Age: 18 years or older;Renal colic;Opioid naive;Informed consent obtained

Exclusion Criteria

- Contra-indications for NSAID's or intranasal opioids;- Opioid tolerant patients

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>the main parameter is the pain reduction after 20 minutes measured on a 100 mm<br /><br>VAS-score. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- The need for butylscopolamin after 20 minutes<br /><br>- Adverse reactions are expressed as being present (=1) or being absent (=0)<br /><br>- The time elapsed until butylscopolamin is administered.<br /><br>- 2 weeks after participation it will be noted whether (=1) or not (=0) the<br /><br>participant presented a second time with renal colics and was treated with<br /><br>butylscopolamine.</p><br>